Cost-of-illness studies in nine Central and Eastern European countries.
Austria
Bulgaria
Central and Eastern Europe
Cost-of-illness
Croatia
Disease burden
Hungary
Poland
Romania
Slovakia
Slovenia
The Czech Republic
Journal
The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
30
03
2019
accepted:
15
04
2019
pubmed:
20
5
2019
medline:
3
1
2020
entrez:
20
5
2019
Statut:
ppublish
Résumé
To date, a multi-country review evaluating the cost-of-illness (COI) studies from the Central and Eastern European (CEE) region has not yet been published. Our main objective was to provide a general description about published COI studies from CEE. A systematic search was performed between 1 January 2006 and 1 June 2017 in Medline, EMBASE, The Cochrane Library, CINAHL, and Web of Science to identify all relevant COI studies from nine CEE countries. COI studies reporting costs without any restrictions by age, co-morbidities, or treatment were included. Methodology, publication standards, and cost results were analysed. We identified 58 studies providing 83 country-specific COI results: Austria (n = 9), Bulgaria (n = 16), Croatia (n = 3), the Czech Republic (n = 10), Hungary (n = 24), Poland (n = 11), Romania (n = 3), Slovakia (n = 3), and Slovenia (n = 4). Endocrine, nutritional, and metabolic diseases (18%), neoplasms (12%), infections (11%), and neurological disorders (11%) were the most frequently studied clinical areas, and multiple sclerosis was the most commonly studied disease. Overall, 57 (98%) of the studies explicitly stated the source of resource use data, 45 (78%) the study perspective, 34 (64%) the costing method, and 24 (58%) reported at least one unit costs. Regardless of methodological differences, a positive relationship was observed between costs of diseases and countries' per capita GDP. Cost-of-illness studies varied considerably in terms of methodology, publication practice, and clinical areas. Due to these heterogeneities, transferability of the COI results is limited across Central and Eastern European countries.
Sections du résumé
BACKGROUND
BACKGROUND
To date, a multi-country review evaluating the cost-of-illness (COI) studies from the Central and Eastern European (CEE) region has not yet been published. Our main objective was to provide a general description about published COI studies from CEE.
METHODS
METHODS
A systematic search was performed between 1 January 2006 and 1 June 2017 in Medline, EMBASE, The Cochrane Library, CINAHL, and Web of Science to identify all relevant COI studies from nine CEE countries. COI studies reporting costs without any restrictions by age, co-morbidities, or treatment were included. Methodology, publication standards, and cost results were analysed.
RESULTS
RESULTS
We identified 58 studies providing 83 country-specific COI results: Austria (n = 9), Bulgaria (n = 16), Croatia (n = 3), the Czech Republic (n = 10), Hungary (n = 24), Poland (n = 11), Romania (n = 3), Slovakia (n = 3), and Slovenia (n = 4). Endocrine, nutritional, and metabolic diseases (18%), neoplasms (12%), infections (11%), and neurological disorders (11%) were the most frequently studied clinical areas, and multiple sclerosis was the most commonly studied disease. Overall, 57 (98%) of the studies explicitly stated the source of resource use data, 45 (78%) the study perspective, 34 (64%) the costing method, and 24 (58%) reported at least one unit costs. Regardless of methodological differences, a positive relationship was observed between costs of diseases and countries' per capita GDP.
CONCLUSIONS
CONCLUSIONS
Cost-of-illness studies varied considerably in terms of methodology, publication practice, and clinical areas. Due to these heterogeneities, transferability of the COI results is limited across Central and Eastern European countries.
Identifiants
pubmed: 31104219
doi: 10.1007/s10198-019-01066-x
pii: 10.1007/s10198-019-01066-x
pmc: PMC6544593
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
155-172Références
Value Health. 2003 Jul-Aug;6(4):407-16
pubmed: 12859580
Pharmacoeconomics. 2005;23(2):113-20
pubmed: 15748086
Pharmacoeconomics. 2005;23(2):143-53
pubmed: 15748089
Health Policy. 2006 Jun;77(1):51-63
pubmed: 16139925
Aliment Pharmacol Ther. 2006 Feb 1;23(3):371-6
pubmed: 16422996
Lancet. 2006 Sep 9;368(9539):917-8
pubmed: 16962878
Pharm World Sci. 2007 Aug;29(4):404-11
pubmed: 17310302
Eur J Health Econ. 2006 Sep;7 Suppl 2:S14-23
pubmed: 17310339
J Rheumatol. 2007 Jun;34(6):1437
pubmed: 17552071
Orv Hetil. 2007 Jul 8;148(27):1259-66
pubmed: 17604262
Pneumologia. 2007 Jul-Sep;56(3):118-23
pubmed: 18019971
Value Health. 2008 Jan-Feb;11(1):13-21
pubmed: 18237356
Eur J Health Econ. 2009 May;10(2):157-65
pubmed: 18618158
Rheumatol Int. 2009 Dec;30(2):199-205
pubmed: 19381635
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Parkinsonism Relat Disord. 2010 Jan;16(1):51-6
pubmed: 19665915
Wien Klin Wochenschr. 2009;121(17-18):574-82
pubmed: 19890747
Rheumatology (Oxford). 2010 Oct;49(10):1920-8
pubmed: 20571123
Value Health. 2010 Dec;13(8):1028-37
pubmed: 20667054
J Nutr Health Aging. 2010 Oct;14(8):633-9
pubmed: 20922339
Wien Med Wochenschr. 2011 Jan;161(1-2):44-52
pubmed: 21312097
Pharmacoeconomics. 2011 Aug;29(8):653-71
pubmed: 21604822
Mult Scler. 2012 May;18(5):662-8
pubmed: 21965424
Gesundheitswesen. 2012 Oct;74(10):e90-8
pubmed: 22422076
Wien Med Wochenschr. 2012 Mar;162(5-6):92-8
pubmed: 22488033
Psychiatr Hung. 2012;27(1):4-17
pubmed: 22493145
Ideggyogy Sz. 2012 Sep 30;65(9-10):316-24
pubmed: 23126217
Pol Arch Med Wewn. 2012;122(12):599-607
pubmed: 23160000
Arch Gynecol Obstet. 2013 Sep;288(3):569-76
pubmed: 23503974
Value Health. 2013 Mar-Apr;16(2):e1-5
pubmed: 23538200
Kardiol Pol. 2013;71(3):224-32
pubmed: 23575775
Pharmacoeconomics. 2013 Jun;31(6):501-8
pubmed: 23620212
Wien Klin Wochenschr. 2013 Jul;125(13-14):402-7
pubmed: 23807043
Eur J Health Econ. 2014 Jul;15(6):653-60
pubmed: 23820625
Pneumologia. 2013 Mar-Jun;62(2):86-92
pubmed: 23894789
PLoS One. 2013 Aug 06;8(8):e71375
pubmed: 23940743
Ideggyogy Sz. 2013 Jul 30;66(7-8):251-61
pubmed: 23971356
Expert Rev Pharmacoecon Outcomes Res. 2014 Jun;14(3):451-8
pubmed: 24702130
Eur J Health Econ. 2014 May;15 Suppl 1:S13-25
pubmed: 24832832
Eur J Health Econ. 2014 May;15 Suppl 1:S27-34
pubmed: 24832833
Eur J Health Econ. 2014 May;15 Suppl 1:S101-9
pubmed: 24832841
Eur Rev Med Pharmacol Sci. 2014;18(10):1499-506
pubmed: 24899609
PLoS One. 2014 Sep 17;9(9):e107704
pubmed: 25229404
Health Policy. 2015 Jul;119(7):964-79
pubmed: 25661982
Pharmacoeconomics. 2015 Aug;33(8):811-31
pubmed: 25787932
Int Urol Nephrol. 2015 Aug;47(8):1241-9
pubmed: 26093585
Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):667-73
pubmed: 26153642
Pharmacoeconomics. 2016 Jan;34(1):43-58
pubmed: 26385101
Folia Med (Plovdiv). 2015 Jan-Mar;57(1):56-64
pubmed: 26431096
Eur Urol. 2016 Mar;69(3):438-47
pubmed: 26508308
Eur J Health Econ. 2017 Jan;18(1):73-82
pubmed: 26743971
PLoS One. 2016 Jan 27;11(1):e0147169
pubmed: 26814959
Int J Technol Assess Health Care. 2015;31(6):434-41
pubmed: 26961722
Eur J Health Econ. 2016 Apr;17 Suppl 1:19-29
pubmed: 27038625
Eur J Health Econ. 2016 Apr;17 Suppl 1:109-17
pubmed: 27038626
Eur J Health Econ. 2016 Apr;17 Suppl 1:99-108
pubmed: 27038627
Eur J Health Econ. 2016 Apr;17 Suppl 1:67-78
pubmed: 27042831
Eur J Health Econ. 2016 Apr;17 Suppl 1:53-65
pubmed: 27048374
Eur J Health Econ. 2016 Apr;17 Suppl 1:7-18
pubmed: 27059622
Eur J Health Econ. 2016 Apr;17 Suppl 1:89-98
pubmed: 27062257
Eur J Health Econ. 2016 Apr;17 Suppl 1:43-52
pubmed: 27072054
Eur J Health Econ. 2016 Apr;17 Suppl 1:31-42
pubmed: 27107597
J Med Econ. 2016 Oct;19(10):973-82
pubmed: 27163169
Med Pr. 2016;67(3):289-99
pubmed: 27364103
PLoS One. 2016 Jul 13;11(7):e0159129
pubmed: 27411042
Neurol Sci. 2016 Dec;37(12):1917-1922
pubmed: 27470305
Qual Life Res. 2016 Nov;25(11):2693-2710
pubmed: 27472992
Eur J Health Econ. 2017 Nov;18(8):979-986
pubmed: 27785577
Pharmacoeconomics. 2017 Mar;35(3):331-345
pubmed: 27848219
Value Health Reg Issues. 2016 Sep;10:53-60
pubmed: 27881278
Acta Dermatovenerol Croat. 2015 Apr;25(1):1-7
pubmed: 28511743
Int Urol Nephrol. 2017 Oct;49(10):1707-1714
pubmed: 28762117
PLoS One. 2017 Aug 14;12(8):e0183116
pubmed: 28806728
Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):223-232
pubmed: 28862060
Lancet. 2017 Sep 16;390(10100):1260-1344
pubmed: 28919118
Health Policy. 2018 Mar;122(3):230-236
pubmed: 29373186
Value Health Reg Issues. 2015 Sep;7:1-8
pubmed: 29698146
Value Health Reg Issues. 2014 Sep;4:75-81
pubmed: 29702811
Value Health Reg Issues. 2013 Sep - Oct;2(2):210-217
pubmed: 29702867